Chief Physician, Party Secretary, Executive President, and Director of the Cancer Center of Peking University International Hospital; Deputy Director of the Department of Internal Medicine at Peking University Cancer Hospital, Professor at Peking University, Doctoral Supervisor. I. Education: Sep 1978 - Jul 1983 Bachelor's Degree, Bethune Medical University Sep 1990 - Jul 1993 Master's Degree, Bethune Medical University Sep 2002 - Jul 2005 Doctoral Degree, Huazhong University of Science and Technology II. Work Experience: 1983 - 1990 The First Clinical College of Bethune Medical University 1993 - 1998 Peking University Cancer Hospital 1998 - 2015 The Affiliated Hospital of Qingdao University Jul 2015 - Present Peking University International Hospital, Peking University Cancer Hospital III. Research Achievements: Undertook or participated in multiple national and provincial/ministerial research projects, including the National Key R&D Program "Precision Medicine Research" Key Special Project, the National 13th Five-Year Key Project - Chinese Cancer Genome Atlas Project, and the National Natural Science Foundation of China. Published dozens of SCI papers. Research achievements have received over 10 national and provincial/ministerial awards, including the Chinese Medical Science and Technology Award and the Huaxia Medical Science and Technology Award. Participated in compiling the Ministry of Health's five-year undergraduate textbook "Introduction to Oncology." As a member of the expert group, participated in formulating multiple guidelines including the National Health and Family Planning Commission's "Diagnosis and Treatment Standards for Primary Liver Cancer," "Diagnosis and Treatment Standards for Cancer Pain," and the Chinese Society of Clinical Oncology's "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer," "Guidelines for the Diagnosis and Treatment of Pancreatic Cancer," "Guidelines for the Diagnosis and Treatment of Gastric Cancer," "Guidelines for the Diagnosis and Treatment of Colorectal Cancer," "Guidelines for the Management of Immune Checkpoint Inhibitor-Related Toxicity," "Guidelines for Nutritional Therapy in Patients with Malignant Tumors," and "Guidelines for the Prevention and Treatment of Antitumor Therapy-Related Nausea and Vomiting." Since beginning work in 1983, has been engaged in tumor-related clinical and scientific research for over 30 years. Specializes in comprehensive and individualized treatment of malignant tumors, particularly digestive system tumors, and has accumulated extensive experience in the diagnosis and treatment of complex and difficult cases. Has visited world-class medical centers multiple times for study and exchange, including the Mayo Clinic in the United States, Gustave Roussy Cancer Center in France, and Heidelberg University Hospital in Germany. Was among the first in China to promote the establishment of a patient-centered, disease-oriented multidisciplinary team (MDT) model. Peking University International Hospital currently has multiple MDT modules including hepatobiliary and pancreatic tumor MDT and gastrointestinal tumor MDT. With deepening understanding of the molecular mechanisms of tumor development and progression and the tumor microenvironment, targeted therapy, immunotherapy, and immuno-combination therapy based on precision diagnosis have brought significant survival benefits to patients. Was among the first in China to pioneer evidence-based medical practice and has accumulated rich clinical experience in related fields. As PI, led or participated in multiple international or domestic multicenter clinical trials covering multiple tumor types including esophageal, gastric, colorectal, and liver cancers, encompassing various directions such as chemotherapy, targeted therapy, and immunotherapy, providing evidence-based medical evidence for the diagnosis, treatment, and management of Chinese cancer patients. For example, the EACH study, based on which the CFDA officially approved the FOLFOX4 regimen containing oxaliplatin for the new indication of advanced liver cancer treatment in 2013, and which has been included and recommended by the US NCCN guidelines for 4 consecutive years since 2015. As Chairman of the CSCO Smart Healthcare Expert Committee, has in recent years been committed to the organic integration of clinical medicine and intelligent technology, leveraging the society's platform to promote industry development. Led and standardized the development of smart healthcare in China's tumor treatment field, and published multiple studies on intelligent medical auxiliary diagnosis and treatment systems at international conferences including ASCO and ESMO. Has also been actively involved in the construction of China's cancer big data, leading and participating in multiple large-scale cancer patient big data surveys, such as a registry study jointly participated by 78 tertiary comprehensive or specialized hospitals nationwide. As the largest liver cancer registry study in China, it has collected diagnosis, treatment, and follow-up data of over 20,000 liver cancer patients, aiming to describe the clinical characteristics, etiology and pathogenesis features, treatment regimens, and outcomes of primary liver cancer in China; analyze the optimal candidate populations for various treatment regimens; explore the optimal clinical pathways for MDT; and provide important reference basis for the prevention and treatment strategies, clinical diagnosis and treatment, and research of primary liver cancer in China. In addition, was among the first in China to promote the localization of international clinical diagnosis and treatment auxiliary systems, making outstanding contributions in the fields of image recognition and natural language recognition. Furthermore, under the funding of the National Key R&D Program "Precision Medicine Research" Key Special Project, has been actively exploring the use of artificial intelligence and big data as bridges to improve patient survival through refined medical decision-making, narrow regional differences in diagnosis and treatment, and explore reasonable pathways for implementing hierarchical diagnosis and treatment.